FDA clears Oramed Pharmaceuticals' IND for ORMD-0801

Download PDF Copy

Editorial Checklist

Reviewed

Oramed Pharmaceuticals Inc.May 17 2013

NewsGuard 100/100 Score

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) for ORMD-0801, its oral insulin capsule.

"We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron , CEO of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

Source:

Oramed Pharmaceuticals Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biotechnology, Diabetes, Drug Delivery, Exenatide, Food, Insulin, New Drug Application, Pharmaceuticals, Type 2 Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Distinct immune profiles linked to adverse reactions from immunotherapy

Distinct immune profiles linked to adverse reactions from immunotherapy

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

FORT-2 trial shows promising results for bladder cancer immunotherapy combination